Alterity Therapeutics Sets FDA-Approved Phase 3 Trial

The company clears a major regulatory hurdle to test its candidate drug for multiple system atrophy in a 200-patient study.

Updated on Oct. 30, 2026 in Biotech

Bold flat-color editorial illustration of a glass medical vial, evoking the precision of clinical drug research. — Alterity Therapeutics has secured formal FDA agreement to advance its neurodegenerative drug candidate ATH434 into a 200-patient Phase 3 trial. AI Illustration. Upload story photo >

Live Poll

Do you generally trust pharmaceutical companies to successfully develop new medical treatments?

Alterity Therapeutics has reached a formal agreement with the FDA on the pivotal Phase 3 trial design for its drug candidate ATH434. The planned study, which aims to enroll approximately 200 patients, will test the efficacy of the 50-milligram treatment over a 12-month period.

Why it matters

This regulatory clearance provides a clear pathway for Alterity to test its candidate against the neurodegenerative condition multiple system atrophy. Data from this pivotal trial, alongside Phase 2 findings, will form the foundation of the company's future new drug application.

The trial measures efficacy using the 11-item Unified Multiple System Atrophy Rating Scale Part I, comparing a 50-milligram twice-daily dose against a placebo. This builds on Phase 2 results that demonstrated a 52% reduction in functional decline over 52 weeks compared to the placebo group.

The players

Alterity Therapeutics

An Australia-based biotechnology company focused on developing small molecule treatments for neurodegenerative diseases including multiple system atrophy.

FDA

The U.S. federal agency responsible for evaluating and regulating drug trial designs and safety protocols to ensure clinical evidence supports new drug applications.

The details

ATH434 is designed as a small molecule drug targeting iron accumulation in the brain, a mechanism associated with multiple system atrophy—a rare, progressive neurodegenerative disorder that impacts autonomic and motor functions. The Phase 3 trial will randomize roughly 200 participants into treatment and control groups to evaluate safety and clinical outcomes over 12 months. The company recently secured U.S. patent protection for the drug's crystalline mesylate salt form, extending coverage until 2045.

August 2026: Alterity secured a U.S. patent for the crystalline mesylate salt form of ATH434.
September 2026: The company ended the financial quarter with $1.34 million in net operating cash outflows.
October 2026: Alterity presented additional Phase 2 analyses for ATH434.

The Tech Race

This agreement aligns Alterity’s development path with the FDA requirements for a new drug application, which mandates one pivotal trial supported by confirmatory evidence. The company is now positioning itself to transition from the Phase 2 data analysis into a definitive Phase 3 assessment.

Patients with multiple system atrophy and their clinicians can look toward this upcoming trial as a formal step toward potential therapy. No specific enrollment dates or site locations have been released to the public yet.

The takeaway

The formalization of the trial design is a critical step in moving ATH434 toward clinical validation. Interested stakeholders should watch for the announcement of the first patient enrollment and the selection of clinical trial sites to gauge the study's operational timeline.